HomeBusinessHealthcareBiogen (BIIB) Stock Soaring, Hopes For FDA Approval
Biogen (BIIB) Stock Soaring, Hopes For FDA Approval

Biogen (BIIB) stock soars following positive Alzheimer’s drug trial. Salim Syed discusses this as Mizuho upgraded BIIB to buy from neutral and raised its price target to $270 from $207. He talks about how this new drug is likely to receive regulatory approval.He then goes over expectations for biopharmaceutical stocks. Tune in to find out more about the stock market today.

The Watch List

28 Sep 2022

ON AIR
7:30 pm
Trading 360
replay
12:00 am
Fast Market
REPLAY
1:00 am
Trading 360
REPLAY
2:00 am
Next Gen Investing
REPLAY
education
3:00 am
Your First Trade
REPLAY
3:30 am
Trading 360
REPLAY
4:30 am
Next Gen Investing
REPLAY
education
5:30 am
Your First Trade
REPLAY
6:00 am
Fast Market
REPLAY
7:00 am
Futures
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
education
3:30 pm
Your First Trade
4:00 pm
Trading 360
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
education
7:00 pm
Your First Trade
REPLAY
ON AIR
7:30 pm
Trading 360
REPLAY
8:30 pm
Fast Market
REPLAY
9:30 pm
Next Gen Investing
REPLAY
education
10:30 pm
Your First Trade
REPLAY
11:00 pm
Trading 360
REPLAY

Get Market Minute

Daily insights for every investor

FOLLOW US